81 assets in Cystic Fibrosis

Therapeutic assets addressing Cystic Fibrosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tezacaftor Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	P4	A (80)
Ivacaftor Cystic Fibrosis	Meyer Children's Hospital IRCCS	P4	BBB (78)
Lumacaftor Cystic Fibrosis	Hospices Civils de Lyon	P4	BBB (78)
Elexacaftor Cystic Fibrosis	Meyer Children's Hospital IRCCS	P4	BBB (76)
vx-121 Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	P3	BBB (74)
Azithromycin Cystic Fibrosis	Hospices Civils de Lyon	P4	BBB (72)
Mannitol Cystic Fibrosis	University of North Carolina, Chapel Hill	P4	BB (69)
Pancrelipase Cystic Fibrosis	Anagram Therapeutics, Inc.	P4	BB (69)
Deutivacaftor Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	P3	BB (68)
Itraconazole Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	P4	BB (65)
XENON Cystic Fibrosis	University of Kansas Medical Center	P4	BB (65)
Galicaftor Cystic Fibrosis	AbbVie	P2	BB (64)
Cefiderocol Cystic Fibrosis	Hartford Hospital	P4	B (62)
Ceftolozane Cystic Fibrosis	Sunshine Coast Hospital and Health Service	P4	B (62)
Tazobactam Cystic Fibrosis	Sunshine Coast Hospital and Health Service	P4	B (62)
Adrulipase Alfa Cystic Fibrosis	Entero Therapeutics	P2	B (60)
Imipenem Cystic Fibrosis	Hartford Hospital	P4	B (59)
Kaftrio Cystic Fibrosis	Hopital Foch	P4	B (59)
Progesterone Cystic Fibrosis	Johns Hopkins University	P4	B (59)
Symdeko Cystic Fibrosis	George Solomon	P4	B (59)
Denosumab Cystic Fibrosis	University of Texas Southwestern Medical Center	P4	B (58)
ETD001 Cystic Fibrosis	Enterprise Therapeutics Ltd	P2	B (58)
Navocaftor Cystic Fibrosis	AbbVie	P2	B (58)
Pseudomonas Aeruginosa-Specific Bacteriophage Mixture, Live Consisting Of 3 Bacteriophages (Ihma-2121771-1, Ihma-2121771-2, Ihma-2121908-1) Cystic Fibrosis	BiomX Ltd	P2	B (58)
Cilastatin Cystic Fibrosis	Hartford Hospital	P4	B (56)
Arct-032 Cystic Fibrosis	Arcturus Therapeutics, Inc.	P2	CCC (55)
Losartan Cystic Fibrosis	University of Kansas Medical Center	P2	CCC (55)
Perflutren Cystic Fibrosis	University of North Carolina, Chapel Hill	P2	CCC (55)
Semaglutide Cystic Fibrosis	University of Minnesota	P2/3	CCC (55)
spl84 Cystic Fibrosis	SpliSense Ltd.	P2	CCC (55)
bi 1291583 Cystic Fibrosis	Boehringer Ingelheim	P2	CCC (54)
Brensocatib Cystic Fibrosis	Insmed Incorporated	P2	CCC (54)
Diponecaftor Cystic Fibrosis	Kors van der Ent	P2	CCC (54)
Abbv-119 Cystic Fibrosis	AbbVie	P2	CCC (53)
Abbv-576 Cystic Fibrosis	AbbVie	P2	CCC (53)
Anakinra Cystic Fibrosis	Heidelberg University	P2	CCC (53)
ang003 Cystic Fibrosis	Anagram Therapeutics, Inc.	P2	CCC (53)
nhs7108 Cystic Fibrosis	Aimmune Nestlé Health Science US R&D, LLC	P2	CCC (53)
Plencifgene Parvec Cystic Fibrosis	4D Molecular Therapeutics	P2	CCC (53)
Sion-719 Cystic Fibrosis	Sionna Therapeutics Inc.	P2	CCC (53)
Tamoxifen Cystic Fibrosis	Azienda Ospedaliera Universitaria Integrata Verona	P2	CCC (53)
Empagliflozin Cystic Fibrosis	University of Minnesota	P2/3	CCC (52)
Maralixibat Cystic Fibrosis	Children's Hospital Los Angeles	P2/3	CCC (52)
Relebactam Cystic Fibrosis	Hartford Hospital	P4	CCC (52)
Rifaximin Cystic Fibrosis	Wake Forest University Health Sciences	P2/3	CCC (52)
Rsp-1502 Cystic Fibrosis	Respirion Pharmaceuticals Pty Ltd	P1/2	CCC (52)
Tenapanor Cystic Fibrosis	Massachusetts General Hospital	P3	CCC (52)
Dulaglutide Cystic Fibrosis	University of Pennsylvania	P2	CCC (51)
Metformin Cystic Fibrosis	University of Kansas Medical Center	P2	CCC (51)
Oligog Dry Powder For Inhalation Cystic Fibrosis	AlgiPharma AS	P2/3	CCC (51)

Showing 1 to 50 of 81 assets

PreviousPage 1 of 2Next